While Indian pharma companies jostle for a share of the rapidly unfolding #semaglutide generics market #EliLilly's next-generation incretin therapy #retatrutide (famously #TripleG) is seen as a game changer with stunning results reported from its recent late-stage clinical trials
And so we really need to be sensitive about the fact that our clinicians and our, the individuals who will be treating these patients really can meet whatever demographic presents itself
On average, participants lost a whopping 26% of their body weight
[DOI] [PubMed] [Google Scholar] 43.Lovric-Bencic M, Sikiric P, Hanzevacki JS, Seiwerth S, Rogic D, Kusec V, Aralica G, Konjevoda P, Batelja L, Blagaic AB
And now you have three structural headwinds for any type of fiscal spend
A 2024 study presented at the American College of Rheumatology conference showed semaglutide users experienced 40 percent greater improvement in knee pain scores compared to placebo after 12 weeks, with continued gains through 52 weeks of observation